Gregory M Cote

23PUBLICATIONS
199CO-AUTHORS
Solid tumoursMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|May 08, 2026
Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplification.

|Jan 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Ezra Y Rosen, Timothy A Yap, Elisa Fontana

|Jan 02, 2026
A Phase 2 Study of Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma.

Gregory M Cote, Mason Aberoumand, Edwin Choy

|Aug 11, 2025
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.

Ecaterina E Dumbrava, Thomas E Stinchcombe, Mrinal Gounder

|Apr 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.

Glenn J Hanna, Gregory M Cote, Rashmi Chugh

|Mar 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.

William D Tap, Gregory M Cote, Howard Burris

Pageof 4

Frequent Collaborators

7 joint publications

Edwin Choy

5 joint publications

Suzanne George

4 joint publications

Geoffrey I Shapiro

4 joint publications

Andrew J Wagner